Hyped growth stocks can be poor investments even when their businesses grow, because valuations already assume they will become exceptional. Retail buyers often arrive after the promise is widely recognized, before tougher competition separates lasting winners from the rest. Eight of the nine previously warned-about stocks have fallen, though Oscar Health has gained. x.com 

Oscar Health cannot be a great business because insurance, like banking, is uninvestable when its economics are nearly impossible to predict. One bad cycle or change in costs can wipe out margins that are already nonexistent. A post the author replies to argues Oscar avoided the 30-40% member drop the market expected after enhanced premium tax credits expired. x.com 

Oscar Health's CEO bought $12 million of stock near the lows, an eight-figure insider buy worth paying attention to. Shares are now at 5.5-year highs and close to threatening the all-time high set at the IPO price. x.com 

Oscar Health's raised 2026 guidance changes nothing fundamentally, so its 18%+ premarket jump is unlikely to hold. Operating earnings guidance rose to $500-700M from $250-450M, but Oscar had already booked $704M in Q1 alone, more than the new top end, with Q3 and Q4 seasonally bringing losses. 2027 could be challenging as management targets a 5% margin, and the stock looks fairly valued around $34. x.com  x.com 

Oscar Health will struggle to climb while Trump keeps attacking insurers in headlines, unless a midterm blue wave or polling pointing to one emerges. Arguments that people will use money to buy Oscar plans matter little under that narrative, and some may skip coverage entirely. Elevance, UnitedHealth and Cigna are the safer way to add insurer exposure here, since employer-sponsored plans are safest, followed by government-sponsored plans, which would gain more from a blue wave. x.com  x.com 

Oscar Health's drop below $30 makes little sense after it crushed Q2, swung to a profit and raised full-year operating earnings guidance. Revenue was $4.90B versus $4.75B expected and EPS $1.10 versus $0.39, with FY26 revenue guided to $18.9B versus $18.6B estimated. The market needs time to digest the result, and the stock should recover soon; it remains a long-term hold. x.com  x.com  x.com 

Oscar Health is essentially a leveraged bet on Affordable Care Act subsidies surviving, and the enhanced premium tax credits are sunsetting. A full lapse would mean roughly a 114% spike in subsidized premiums and enrollment cratering into 2027. Q2 was a monster print, with EPS of $1.10 versus $0.39 expected, but the real test comes next year. x.com 

Oscar Health is too hard to invest in given the state of the ACA, uncertainty over how much ICHRA can add and uncertain risk-adjustment liabilities. A full-year medical loss ratio below 80% would force rebates, though Oscar can still cut its expense ratio. Democrats winning at least partially in the midterms could bring more favorable terms for Oscar later. x.com 

Oscar Health's record Q1 and CEO insider buying set it up to break out of a 24-month accumulation base. The tech-driven insurer, spanning ACA, Medicare and small-group markets, grew revenue 53% and earned $2.07 a share versus $1.11 expected, and its CEO bought 1 million shares in April. A clean close above $24, where it has been rejected repeatedly, is needed before it heads higher. x.com 

Oscar Health still has a lot of room to run, provided regulations are favorable and the company keeps executing. x.com